CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?

  • Tettamanti S
  • Biondi A
  • Biagi E
 et al. 
  • 37


    Mendeley users who have this article in their library.
  • 8


    Citations of this article.


Chimeric antigen receptor (CAR) modified T cells have emerged as powerful tools for controlling leukemias. We recently showed that anti-CD123 CAR-expressing cytokine-induced killer T cell treatment is an effective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML) cells. Here, we discuss how this genetically modified cell-based strategy could be relevant to the field of AML therapeutics.

Author-supplied keywords

  • AML
  • Anti-CD123
  • CAR-T cells
  • Immunotherapy
  • Leukemic stem cells

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free